Table 2 Pathways enriched in temporal patterns by SST
| Â | Â | Pathways from temporal up-pattern (KEGG ID) | P-value* | FDR** | Pathways from temporal down-pattern (KEGG ID) | P-value | FDR |
|---|---|---|---|---|---|---|---|
All genes | Simple enrichment analysis | Cell cycle (mmu04110) | 8.41E-05 | 9.62E-03 | Drug metabolism-cytochrome P450 (mmu00982) | 3.57E-10 | 3.07E-08 |
Systemic lupus erythematosus (mmu05322) | 7.97E-10 | 3.43E-08 | |||||
Complement and coagulation cascades (mmu04610) | 3.45E-08 | 9.88E-07 | |||||
Retinol metabolism (mmu00830) | 4.38E-08 | 9.41E-07 | |||||
Metabolism of xenobiotics by cytochrome P450 (mmu00980) | 1.15E-06 | 1.97E-05 | |||||
Linoleic acid metabolism (mmu00591) | 2.04E-06 | 2.92E-05 | |||||
Prion diseases (mmu05020) | 2.43E-05 | 2.99E-04 | |||||
PPAR signaling pathway (mmu03320) | 3.42E-05 | 3.67E-04 | |||||
Drug metabolism-other enzymes (mmu00983) | 4.87E-04 | 4.64E-03 | |||||
Topology-based signaling pathway analysis | Â | Â | Â | Systemic lupus erythematosus (mmu05322) | 1.74E-10 | 1.36E-08 | |
Complement and coagulation cascades (mmu04610) | 4.55E-10 | 1.77E-08 | |||||
Cytokine-cytokine receptor interaction (mmu04060) | 1.69E-08 | 1.84E-06 | Prion diseases (mmu05020) | 2.82E-07 | 7.33E-06 | ||
Osteoclast differentiation (mmu04380) | 4.88E-06 | 2.66E-04 | PPAR signaling pathway (mmu03320) | 1.42E-06 | 2.78E-05 | ||
Cell cycle (mmu04110) | 1.52E-04 | 5.55E-03 | Staphylococcus aureus infection (mmu05150) | 3.48E-06 | 5.42E-05 | ||
| Â | Â | Â | Serotonergic synapse (mmu04726) | 1.18E-05 | 1.53E-04 | ||
Alcoholism (mmu05034) | 2.48E-04 | 2.77E-03 | |||||
Endocrine and other factor-regulated calcium reabsorption (mmu04961) | 7.76E-04 | 7.57E-03 | |||||
MicroRNA targets | Simple enrichment analysis | No pathway | Â | Â | Metabolism of xenobiotics by cytochrome P450 (mmu00980) | 1.45E-04 | 3.19E-03 |
Topology-based signaling pathway analysis | Cell cycle (mmu04110) | 5.46E-03 | 1.00E-02 | No pathway | Â | Â | |
Non-microRNA targets | Simple enrichment analysis | No pathway | Â | Â | Systemic lupus erythematosus (mmu05322) | 1.63E-10 | 1.22E-08 |
Complement and coagulation cascades (mmu04610) | 9.24E-09 | 3.46E-07 | |||||
Drug metabolism (mmu00982) | 1.94E-07 | 4.85E-06 | |||||
Prion diseases (mmu05020) | 1.20E-05 | 2.26E-04 | |||||
Retinol metabolism (mmu00830) | 2.82E-05 | 4.22E-04 | |||||
Linoleic acid metabolism (mmu00591) | 2.01E-04 | 2.51E-03 | |||||
PPAR signaling pathway (mmu03320) | 8.76E-04 | 9.34E-03 | |||||
Topology-based signaling pathway analysis | Cytokine-cytokine receptor interaction (mmu04060) | 1.63E-07 | 1.42E-05 | Systemic lupus erythematosus (mmu05322) | 3.95E-11 | 3.00E-09 | |
Complement and coagulation cascades (mmu04610) | 1.31E-10 | 4.97E-09 | |||||
Prion diseases (mmu05020) | 1.32E-07 | 3.34E-06 | |||||
NF-kappa B signaling pathway (mmu04064) | 2.37E-05 | 8.95E-04 | Staphylococcus aureus infection (mmu05150) | 1.63E-06 | 3.10E-05 | ||
MAPK signaling pathway (mmu04010) | 3.09E-05 | 8.95E-04 | Serotonergic synapse (mmu04726) | 5.15E-05 | 7.83E-04 | ||
Osteoclast differentiation (mmu04380) | 4.17E-04 | 9.07E-03 | PPAR signaling pathway (mmu03320) | 9.33E-05 | 1.18E-03 | ||
Endocrine and other factor-regulated calcium reabsorption (mmu04961) | 6.65E-04 | 7.22E-03 | |||||
| Â | Â | Â | Â | Â | Alcoholism (mmu05034) | 9.07E-04 | 8.61E-03 |